Exelixis Inc. [NASDAQ: EXEL] closed the trading session at $17.71 on 07/13/21. The day’s price range saw the stock hit a low of $17.66, while the highest price level was $18.14. The company report on July 9, 2021 that Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021.
– Presentation to be webcast on www.exelixis.com –.
Exelixis, Inc. (Nasdaq: EXEL) announced that Peter Lamb, Ph.D., the company’s Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT.
The stocks have a year to date performance of -11.76 percent and weekly performance of -3.70 percent. The stock has been moved at -26.67 percent over the last six months. The stock has performed -22.93 percent around the most recent 30 days and changed -24.38 percent over the most recent 3-months.
If compared to the average trading volume of 2.09M shares, EXEL reached to a volume of 1628295 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Exelixis Inc. [EXEL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXEL shares is $29.93 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXEL stock is a recommendation set at 1.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Exelixis Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 15, 2021. While these analysts kept the previous recommendation, Goldman raised their target price to Sell. The new note on the price target was released on May 18, 2021, representing the official price target for Exelixis Inc. stock. Previously, the target price had yet another raise to $30, while Credit Suisse analysts kept a Outperform rating on EXEL stock.
The Average True Range (ATR) for Exelixis Inc. is set at 0.78, with the Price to Sales ratio for EXEL stock in the period of the last 12 months amounting to 5.33. The Price to Book ratio for the last quarter was 2.89, with the Price to Cash per share for the same quarter was set at 3.82. Price to Free Cash Flow for EXEL in the course of the last twelve months was 36.24 with Quick ratio for the last quarter at 6.60.
EXEL stock trade performance evaluation
Exelixis Inc. [EXEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.70. With this latest performance, EXEL shares dropped by -22.93% in over the last four-week period, additionally sinking by -26.67% over the last 6 months – not to mention a drop of -25.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXEL stock in for the last two-week period is set at 29.06, with the RSI for the last a single of trading hit 26.76, and the three-weeks RSI is set at 31.61 for Exelixis Inc. [EXEL]. The present Moving Average for the last 50 days of trading for this stock 22.21, while it was recorded at 17.91 for the last single week of trading, and 22.14 for the last 200 days.
Exelixis Inc. [EXEL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Exelixis Inc. [EXEL] shares currently have an operating margin of +11.14 and a Gross Margin at +96.33. Exelixis Inc.’s Net Margin is presently recorded at +11.32.
Return on Total Capital for EXEL is now 6.00, given the latest momentum, and Return on Invested Capital for the company is 6.10. Return on Equity for this stock inclined to 6.27, with Return on Assets sitting at 5.53. When it comes to the capital structure of this company, Exelixis Inc. [EXEL] has a Total Debt to Total Equity ratio set at 2.77. Additionally, EXEL Total Debt to Total Capital is recorded at 2.70, with Total Debt to Total Assets ending up at 2.43. Long-Term Debt to Equity for the company is recorded at 2.61, with the Long-Term Debt to Total Capital now at 2.54.
Reflecting on the efficiency of the workforce at the company, Exelixis Inc. [EXEL] managed to generate an average of $144,607 per employee. Receivables Turnover for the company is 6.92 with a Total Asset Turnover recorded at a value of 0.49.Exelixis Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.60 and a Current Ratio set at 6.70.
Exelixis Inc. [EXEL]: Insider Ownership positions
There are presently around $4,693 million, or 85.30% of EXEL stock, in the hands of institutional investors. The top three institutional holders of EXEL stocks are: BLACKROCK INC. with ownership of 32,110,132, which is approximately 2.302% of the company’s market cap and around 1.70% of the total institutional ownership; VANGUARD GROUP INC, holding 29,400,178 shares of the stock with an approximate value of $520.68 million in EXEL stocks shares; and PRICE T ROWE ASSOCIATES INC /MD/, currently with $367.2 million in EXEL stock with ownership of nearly 17.886% of the company’s market capitalization.
Positions in Exelixis Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 161 institutional holders increased their position in Exelixis Inc. [NASDAQ:EXEL] by around 24,336,253 shares. Additionally, 175 investors decreased positions by around 21,540,311 shares, while 61 investors held positions by with 219,118,901 shares. The mentioned changes placed institutional holdings at 264,995,465 shares, according to the latest SEC report filing. EXEL stock had 47 new institutional investments in for a total of 3,160,934 shares, while 50 institutional investors sold positions of 3,594,684 shares during the same period.